Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Decisions On New Off-Label Chemotherapy Compendia Due By Early July

Executive Summary

CMS will issue decisions by early July on the possible addition of four medical compendia as approved references for coverage of off-label uses of cancer drugs and biologicals
Advertisement

Related Content

DrugDex Endorsed As Off-Label Chemotherapy Guide For Medicare Coverage
DrugDex Endorsed As Off-Label Chemotherapy Guide For Medicare Coverage
Off-Label Dissemination Keeps FDA Stuck Between Prosecutors And Firms
CMS approves off-label chemotherapy compendium
CMS approves off-label chemotherapy compendium
Off-Label Dissemination Keeps FDA Stuck Between Prosecutors And Firms
Broader off-label coverage under Part D
Broader off-label coverage under Part D
UnitedHealth To Rely On NCCN Compendium For Off-Label Oncology Coverage
CMS modifies anti-cancer compendia rules
Advertisement
UsernamePublicRestriction

Register

PS049503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel